SilverOak Wealth Management LLC Raises Position in Solventum Co. (NYSE:SOLV)

SilverOak Wealth Management LLC lifted its position in Solventum Co. (NYSE:SOLV) by 5.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,559 shares of the company’s stock after buying an additional 1,118 shares during the period. SilverOak Wealth Management LLC’s holdings in Solventum were worth $1,490,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in SOLV. Modus Advisors LLC purchased a new position in Solventum in the 4th quarter worth about $25,000. Copeland Capital Management LLC purchased a new position in shares of Solventum during the third quarter valued at approximately $26,000. Stonebridge Financial Group LLC purchased a new stake in Solventum in the fourth quarter worth approximately $26,000. Crews Bank & Trust bought a new stake in Solventum in the 4th quarter worth approximately $32,000. Finally, True Wealth Design LLC raised its stake in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after buying an additional 471 shares during the last quarter.

Solventum Price Performance

SOLV opened at $74.27 on Wednesday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a 50 day simple moving average of $70.91 and a two-hundred day simple moving average of $68.88. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Analyst Upgrades and Downgrades

SOLV has been the subject of several research analyst reports. Piper Sandler lifted their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Mizuho assumed coverage on shares of Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target for the company. Finally, Morgan Stanley raised their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, Solventum currently has a consensus rating of “Hold” and an average target price of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.